Molecularly-Targeted Strategy and NF-κB in Lymphoid Malignancies

DOI PubMed 3 Citations 100 References Open Access
  • Horie Ryouichi
    Department of Hematology, School of Medicine, Kitasato University

Bibliographic Information

Other Title
  • Molecularly-Targeted Strategy and NF-^|^kappa;B in Lymphoid Malignancies

Search this article

Description

Molecularly-targeted therapy is a promising strategy for the treatment of cancer. Nuclear factor (NF)-κB is a transcription factor that is constitutively activated in various lymphoid malignancies and may therefore be a good therapeutic target. Lymphoid malignancies arise from different stages of normal lymphocyte differentiation and acquire distinct pathways for constitutive NF-κB activation. However, no NF-κB inhibitor has yet been successfully applied in clinical medicine. This review focuses on the concept of molecularly-targeted therapeutics with small molecule drugs, molecular mechanisms of constitutive NF-κB activation in lymphoid malignancies, and the development of NF-κB inhibitors. A future perspective regarding the development of NF-κB inhibitors is also included. [J Clin Exp Hematop 53(3) : 185-195, 2013]

Journal

Citations (3)*help

See more

References(100)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top